MURA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. MURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MURA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

MURA had negative earnings in the past year.
MURA had a negative operating cash flow in the past year.

1.2 Ratios

The Return On Assets of MURA (-181.12%) is worse than 88.70% of its industry peers.
MURA has a Return On Equity of -215.81%. This is in the lower half of the industry: MURA underperforms 70.24% of its industry peers.

		Industry Rank	Sector Rank
ROA	-181.12%
ROE	-215.81%
ROIC	N/A

ROA(3y)-235.67%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, MURA has more shares outstanding
There is no outstanding debt for MURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -7.55, we must say that MURA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.55, MURA is not doing good in the industry: 68.74% of the companies in the same industry are doing better.
There is no outstanding debt for MURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.55

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

MURA has a Current Ratio of 5.90. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MURA (5.90) is better than 61.21% of its industry peers.
MURA has a Quick Ratio of 5.90. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.90, MURA is in the better half of the industry, outperforming 62.52% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	5.9
Quick Ratio	5.9

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.16% over the past year.

EPS 1Y (TTM)24.16%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%88.77%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

MURA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.94% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y23.84%

EPS Next 2Y39.55%

EPS Next 3Y25.65%

EPS Next 5Y11.94%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.